Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and LegoChem Biosciences (LCB) (KOSDAQ:141080), a South Korean company with a proprietary antibody drug conjugate (ADC) technology, have entered into a research collaboration to evaluate an antibody drug conjugate candidate.
LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology. In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.
“Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients”, said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.
ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells. Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.